Opinion
Video
Treatment Options for Advanced Parkinson Disease
Author(s):
Panelists discuss how alternative formulations and administration routes like Levodopa/carbidopa intestinal gel and deep brain stimulation have impacted advanced Parkinson disease management, including which patient populations benefit most and when these options are recommended.
Video content above is prompted by the following:
Impact of Advanced Treatment Options in Managing Parkinson Disease: A Summary for Physicians
Advanced Treatment Modalities in Parkinson Disease
Advanced Parkinson disease (PD) management has evolved significantly with the introduction of alternative delivery systems and surgical interventions that provide more consistent dopaminergic stimulation or modulation of basal ganglia circuitry.
Key Advanced Treatment Options
Levodopa/Carbidopa Intestinal Gel (LCIG)
- Delivers continuous intestinal infusion via PEG-J tube
- Bypasses gastric emptying variability
- Provides more stable plasma levodopa levels
Deep Brain Stimulation (DBS)
- Primary targets: subthalamic nucleus and globus pallidus interna
- Modulates abnormal neural activity in basal ganglia circuits
- Reduces medication requirements post-implantation
Continuous Subcutaneous Apomorphine Infusion
- Dopamine agonist delivered via portable pump
- Maintains consistent dopaminergic stimulation
- Alternative for patients unsuitable for surgical options
Patient Selection and Optimal Timing
Ideal Candidates for Advanced Therapies
LCIG is Most Beneficial For:
- Patients with severe motor fluctuations and dyskinesias
- Those with cognitive impairment (relative contraindication for DBS)
- Elderly patients where surgical risk of DBS may be prohibitive
DBS Shows Greatest Benefit In:
- Patients with levodopa-responsive symptoms
- Those with troublesome motor fluctuations or dyskinesias
- Younger patients (<70-75 years) with minimal cognitive/psychiatric issues
- Patients without significant axial symptoms unresponsive to levodopa
Timing Considerations:
- Advanced therapies are typically considered when optimized oral medication regimens fail to adequately control motor fluctuations
- Evidence suggests earlier intervention with DBS (within 4-7 years of diagnosis) may provide superior outcomes compared to delayed intervention
- Treatment should be initiated before significant disability develops but after motor complications become problematic
- The window between development of motor complications and emergence of levodopa-resistant symptoms represents the optimal intervention period
Clinical Implementation Recommendations:
- Comprehensive multidisciplinary assessment is essential before initiating advanced therapies
- Regular reassessment of disease progression should prompt consideration of advanced options before quality of life significantly deteriorates
- Patient preferences, cognitive status, comorbidities, and social support systems should heavily influence treatment selection
- Referral to specialized movement disorder centers is recommended when considering these interventions
These advanced therapies have transformed management of complicated PD, offering improved symptom control and quality of life for appropriately selected patients when conventional pharmacotherapy becomes inadequate.
